trending Market Intelligence /marketintelligence/en/news-insights/trending/IL5ScXdnlU-QCaY5ofrgpw2 content esgSubNav
In This List

Osmotica Pharmaceuticals adds board member

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Osmotica Pharmaceuticals adds board member

Osmotica Pharmaceuticals PLC appointed Gregory Cowan to its board of directors and audit committee, effective Jan. 2, 2019.

Cowan previously served as executive vice president and CFO of Avantor Inc.

Bridgewater, N.J.-based Osmoticsa develops specialty products for underserved patient populations. Its products include M-72 for attention deficit hyperactivity disorder and Osmolex ER for Parkinson's and drug-induced extrapyramidal reactions in adults.